Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+], BRCA-mutated advanced breast cancer

platelet count
liver metastasis
herceptin
HER2
urine test
  • 7 views
  • 27 Jan, 2021
  • 27 locations
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

This study will evaluate the activity of single agent trastuzumab or lapatinib in patients not previously treated for HER-2 positive (FISH positive) metastatic breast cancer. A companion

erbb2
breast cancer
liver metastasis
lapatinib
endocrine therapy
  • 1 views
  • 07 Nov, 2020
  • 1 location
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

This is a randomized, open, parallel-controlled, multicenter, phase II/III, seamless design clinical trial to compare the efficacy and safety of RC48-ADC with capecitabine + lapatinib in locally

growth factor
capecitabine
immunostimulant
ejection fraction
HER2
  • 128 views
  • 17 Jul, 2021
  • 69 locations
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+ HER2+ Advanced Breast Cancer Patients

better PFS than ET alone (TAnDEM trial and trial comparing lapatinib plus letrozole versus letrozole alone) [2],[3] confirming existence of cross talk between ER and HER2 pathways in clinical setting

chromogenic in situ hybridization
endocrine therapy
pertuzumab
ejection fraction
HER2
  • 0 views
  • 26 Jan, 2021
  • 1 location
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose), given in combination with trastuzumab administered through the vein, in patients with HER2-amplified Metastatic Breast Cancer that has gotten …

growth factor
erbb2
muga scan
mammogram
renal function test
  • 36 views
  • 10 Mar, 2021
  • 1 location
Selective Treatment According to Molecular Subtype of Prostate Cancer

This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers. Depending on the expression of these markers, the patients will be characterize as group 1 (Luminal …

testosterone
serum testosterone
  • 1 views
  • 22 Jan, 2021
  • 1 location
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

BACKGROUND: Gastric cancer is one of the most common cancers and is one of the most deadly cancers. Most patients have advanced disease and should receive first-line trastuzumab-associated chemotherapy when the biopsy is positive for immunocytochemical expression and / or HER2 gene amplification. A study conducted by our group noted …

  • 0 views
  • 03 Feb, 2021
  • 1 location
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2

adenocarcinoma of the breast
progesterone receptor
cancer
immunohistochemistry
breast cancer
  • 0 views
  • 22 Aug, 2021
  • 1 location